Cytokinetics Inc vs iShares Self-Driving EV and Tech — how do they compare? Cytokinetics Inc trades at $62.69 (market cap $8.62B), while iShares Self-Driving EV and Tech trades at $33.17 (market cap $264.50M). The key difference: Cytokinetics Inc is far larger — about 32.6× iShares Self-Driving EV and Tech's market cap, and Cytokinetics Inc is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and iShares Self-Driving EV and Tech for 73 Days on average.
| CYTK | IDRV | |
|---|---|---|
Market Cap | $8.62B | $264.50M |
Volume | 2,594,626 | 48,021 |
Sector | Health | Sector/Thematic |
52-Week High | $87.26 | $45.48 |
52-Week Low | $54.76 | $32.68 |
Typical Hold Time | 19 Days | 73 Days |
Enterprise Value | $8.72B | — |
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →